Sullivan, Ryan J <br/><br/>
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.  [electronic resource] 

 -  Cancer discovery  02 2018 
 - 184-195 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2159-8290 
<br/><br/><label>Standard No.: </label>10.1158/2159-8290.CD-17-1119  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Aminopyridines--pharmacology<br/>Female<br/>Humans<br/>Magnetic Resonance Imaging<br/>Male<br/>Middle Aged<br/>Mitogen-Activated Protein Kinase 1--antagonists & inhibitors<br/>Mitogen-Activated Protein Kinase 3--antagonists & inhibitors<br/>Mitogen-Activated Protein Kinases--genetics<br/>Mutation<br/>Neoplasm Staging<br/>Neoplasms--diagnosis<br/>Protein Kinase Inhibitors--pharmacology<br/>Pyrroles--pharmacology<br/>Tomography, X-Ray Computed<br/>Treatment Outcome<br/>Young Adult